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Accurate and noninvasive stem cell tracking is one of the most important needs in regenerative medicine to determine both stem
cell destinations and final differentiation fates, thus allowing a more detailed picture of the mechanisms involved in these therapies.
Given the great importance and advances in the field of nanotechnology for stem cell imaging, currently, several nanoparticles have
become standardized products and have been undergoing fast commercialization.This review has been intended to summarize the
current use of different engineered nanoparticles in stem cell tracking for regenerativemedicine purposes, in particular by detailing
theirmain features and exploring their biosafety aspects, the first step for clinical application.Moreover, this review has summarized
the advantages and applications of stem cell tracking with nanoparticles in experimental and preclinical studies and investigated
present limitations for their employment in the clinical setting.
1. Introduction
The main purpose of regenerative medicine is to restore
damaged or ageing tissues by mimicking their native mor-
phology and function. In this concern, during the last
years, advances in this field have been strictly correlated
with new and promising approaches in tissue engineering,
bioengineering, nanotechnology, and stem cell (SC) biology,
thereby addressing extremely topical issues from a marked
interdisciplinary perspective [1].
The newest therapeutic strategies in regenerative
medicine are often directed to favor the intrinsic self-
regenerating ability of the tissues and thus principally rely
on techniques based on the use of specific soluble growth
factors, biomaterials, and especially stem or progenitor cells
(SCs/PCs).
Indeed, to ensure that these treatments are a success, it
is essential to determine the fate of SCs, their functional
capabilities, and the biological role that they play.
In this review, we will first introduce the most relevant
cell types for regenerative medicine purposes; then, we will
elucidate the main features of the available nanoparticles
(NPs) for SC tracking, focusing on their biosafety aspects;
lastly, we will describe some examples of NP applications for
fluorescent, magnetic resonance and photoacoustic imaging
of SCs in in vivomodels.
2. Stem Cells for Regenerative
Medicine Purposes
SCs can be defined as unspecialized cells capable of both
self-renewal potential, that is, the ability to retain their
stemness through controlled proliferation, and commitment
to differentiation into one or more mature cell types in the
body [2].
For the purpose of regenerativemedicine approaches, SCs
should answer to specific criteria: (a) great availability, that is,
SCs should be found in abundant quantities; (b) noninvasive
procedures to harvest them; (c) regulated and reproducible
ways to gain specific differentiated cell lineages from starting
SCs; (d) efficient and safe autologous or allogeneic transplan-
tations into patients; and (e)manipulation in accordancewith
the “Good Manufacturing Practice” guidelines [3].
Among the several suitable SCs populations, embryonic
stem cells (ESCs) were first isolated from mouse embryos
[4, 5] and can be defined as a pluripotent cell lineage
deriving from the epiblast tissue of the inner cell mass of
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the blastocyst. Although this population has been extensively
used in regenerative medicine, several studies underlined
ethical problems for its clinical application [6, 7]. Other
works then proposed the use of the more upstanding induced
pluripotent stem cells (iPSCs), that is, somatic cells that are
reprogrammed for pluripotency via the overexpression of a
specific set of genes [8–11]. Nevertheless, the main issue for
both ESCs and iPSCs is the ability to form teratomas [12–
14], which are considered a major obstacle for biomedical
applications [15]; in addition, iPSCs have also been associated
to marked tumorigenic activity [16].
Besides pluripotent SCs, in the adults, many organs
posses tissue-specific populations of SCs which can give rise
to differentiated cell lineages appropriate for their location,
therefore not fulfilling the principle of pluripotency and,
with respect to ESCs and iPSCs, being less self-renovating
[17]. Among the different tissue-specific SCs, including
hematopoietic [18] and neuronal [19] SCs,mesenchymal stem
cells (MSCs) are probably the most important population
applicable in human regenerative medicine.
MSCs are defined as a population of multipotent stromal
cells that can be isolated from a variety of both adult and
fetal tissues, including bone marrow [20], still the major
source, adipose tissue [21], placenta [22], and umbilical cord
[23], with the capability to differentiate, under appropriate
conditions, into chondrocytes, osteoblasts, and adipocytes
and to commit to neurons, cardiomyocytes, and endothelial
cells [17, 20, 24–27].
Unlike ESCs and iPSCs, MSCs do not have ethical prob-
lems, can be easily obtained in large amounts from patient’s
own tissue (especially bone marrow and fat), and present an
extremely low risk of tumorigenesis, although they are not
completely free ofmalignant transformation [28].MSCs have
been proposed as a powerful tool for the treatment of various
pathologies, including immune and degenerative disorders
[29, 30], and prevention of left ventricular remodeling after
myocardial infarction [31].
During the past years, it was believed that the therapeutic
outcome of transplanted MSCs was principally due to cell
engraftment and differentiation at the site of injury. However,
only a small percentage of deliveredMSCs survive and engraft
after transplantation, while it has become evident that these
cells exert positive effects on the host tissue by preferentially
secreting a variety of paracrine/autocrine factors, the so-
called secretome [32], which may generate in the injured
tissue amicroenvironment that can support regenerative pro-
cesses, induce angiogenesis, and protect against further tissue
death [29, 33]. Additionally, transplantedMSCs have demon-
strated immunomodulatory properties, low immunogenicity,
and the capability to reduce oxidative stress and inflamma-
tion by direct interactionwith neutrophils, macrophages, and
monocytes [31].
In addition to direct transplantation or injection, MSCs
may also be delivered through the implant of biocompat-
ible natural or synthetic scaffolds made up to mimic the
regulatory characteristics of natural extracellular matrices
(ECMs) and ECM-bound growth factors [34]. There are
generally three main methods to generate MSCs/scaffold
grafts: (a) cells can be expanded in vitro and seeded on
the scaffold before implantation into the body’s patient [35–
38], (b) several days before transplantation, undifferentiated
MSCs can be loaded onto the scaffold and induced to
differentiate towards a specific lineage [39–41], and (c) the
scaffold can be functionalized with SC-attractive molecules
and then acellularized scaffolds are implanted allowing in situ
regeneration through recruitment of autologous cells [42, 43].
Advances in preclinical research demonstrating the safety
and feasibility of MSCs transplantation in different patholo-
gies, such as myocardial infarction, stroke, regeneration
of bone and cartilage defects, spinal cord injury, graft-
versus-host disease, and blood disorders, have paved the
way to translation of MSC-based therapies in clinical set-
tings all over the world [44]. Although several clinical
trials employing MSCs transplantation have been listed in
public databases, among them ClinicalTrials.gov for USA
(http://clinicaltrials.gov/) and Clinical Trials Register for
EU (https://www.clinicaltrialsregister.eu/index.html), how-
ever, still few approaches have been translated into humans.
One reason is that, in order to assess the outcome of
therapies with SCs and to develop more efficient therapies,
the clinicians need to determine in real time the physiological
state of engrafted cells and to monitor their survival in
patients. However, the exact mechanisms at the base of SC
distribution and engraftment and, especially, the balance
within these processes remain elusive [45, 46]. Indeed, the
often poor survival of engrafted cells, due to an adverse host
tissue microenvironment or to inadequate nutrient support,
may compromise the outcome of SC therapies [47].
Based on these considerations, during the last few years,
several research groups examined safe ways to track the
movement of the implanted SCs in the target tissue and
generally inside the host with the attempt to guarantee
long-term analysis of cell survival, migration, redistribution,
and differentiation, besides understanding the best injection
method for cell delivery.
3. A Brief Overview on Stem Cell
Tracking Methods
Traditionalmethods to follow implanted SC fate forecasted in
vitro cell labeling before cell transplantation and subsequent
follow-up of cell engraftment and survival through the anal-
ysis of histological sections coming from sacrificed animals
or tissue biopsies, an invasive technique that did not permit
long-term and continuous analyses [48, 49].
Recent advances in SC therapy require more accurate
and noninvasive methods for qualitatively and quantitatively
monitoring transplanted cells inside the host, in order to facil-
itate the understanding of treatment outcomes and ultimately
improve patients handling [50].
The most common techniques take advantage of spe-
cific contrast agents, such as endogenous biomolecules with
intrinsic fluorescence [51], exogenous fluorescent proteins
[52], or nonfluorescent organic dyes [53], which have been
used for essentially two labeling modalities: (a) direct
labeling, that is, cell incubation with specific intracellular
probes, and (b) indirect labeling, through the expression
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of the indicator by a reporter gene inserted in the genome
of the cells. Direct methods are easy to apply and less
expensive, however, potential limitations include fast signal
decay due to cell proliferation and subsequent insufficient
marker distribution between daughter cells. On the other
hand, indirect techniques are much more stable but require
genetic manipulation of cells and may not be suitable for
clinical applications [54].
In general, the majority of the employed contrast agents
often present disadvantages like photo-bleaching over time,
interference derived from tissue autofluorescence, chemi-
cal and/or metabolic degradation in vivo, and even low
transfection efficiency in primary cells and thus are not
considered suitable for in vivo imaging. To overcome this
limitation, several engineered NPs with unique magnetic
and/or optical properties have been developed and employed
in biomedicine, due to their capability to offer real-time
methods of tracking intracellular processes at a biomolecular
level [55–57].
4. Nanoparticles to Track Stem Cells
Over the last years, the definition of “nanoparticle” or “nano-
material” has been controversial. Currently, the most used
criterion to define NPs is size [58, 59]; in October 2011, the
European Commission (EC) published a recommendation
(2011/696/EU) [60] on the definition of “nanomaterial” as
“a natural, incidental or manufactured material containing
particles, in an unbound state or as an aggregate or as an
agglomerate andwhere, for 50%ormore of the particles in the
number size distribution, one or more external dimensions is
in the size range 1 nm–100 nm”. However, other parameters
have been used; for example, amore recent definition focused
on the importance of NP surface area; indeed, as the particle
size decreases, its specific surface area increases allowing
a greater proportion of its atoms to be displayed on the
surface. Focusing on this characteristic, the new definition
indicates that a NP should have a surface area > 60m2/cm3
[61, 62]. New synthesis techniques allowed for producing
not only spherical NPs, but also other shapes such as cube
[63, 64], prism [65, 66], hexagon [64, 67], octahedron [68],
rod [69, 70], and tube [71]. Importantly, morphology and
size determine the physicochemical properties of the NPs,
as they lead to different cellular uptake and interaction with
biological tissues that would not be possible using the bulk
material [72].
Before practical use, NPs should undergo a comprehen-
sive characterization in terms of purity, that is, the fraction
of NP composition beyond chemical and biological contam-
inants, and physicochemical features in both dry and wet
conditions [73, 74]. Furthermore, it is commonly accepted
that the contact of NPs with a biological environment leads to
the adsorption of biomolecules such as proteins and lipids on
thematerial surface.The possibility that this interface’s events
implicate a constitution of new bioactive sites on NPs surface
has been the focus of several papers [75, 76]. Interestingly,
different studies have highlighted that this biological corona
exposes specific epitopes that are specific to the NP surface
propriety [77, 78] and to the time and the biological media in
which they are exposed [79–82].
Besides tracking living transplanted cells [83], which
represents the target of the present review, engineered nano-
materials have also being exploited for other applications,
among them, industrial products such as topical sunscreens
and cosmetics, inks food products, and toothpastes. In the
context of biomedical application, NPs have been investi-
gated for drug or gene delivery [84–86] and for nanoth-
eranostics [87], a branch of medicine that can be applied
to noninvasively discover and target markers and deliver
treatments based on biomarker distribution, in order to gain
both diagnosis and therapy for several pathologies [88]. In
particular, some NPs are currently used in clinical trials for
cancer thermal therapy [89–91]. Despite the great interest in
these promising applications, the focus of the present review
is to introduce to the readers the application of NPs for
SC tracking.
5. Biosafety Profiles of Nanoparticles
Used to Track Stem Cells
In general, NP technology applied for in vivo noninvasive SC
tracking must allow long-term and sensitive localization of
the cells avoiding cytotoxicity as much as possible. However,
it is important to underline that almost no NPs have been
used for therapeutic SC tracking into patients yet.The reason
is that, before any approval for clinical use, there must be a
fundamental step of NP characterization for both chemical
composition and biological effects on SCs, including viability
rate after loading, influence on SC migration, differentiation,
engraftment, and evaluation of possible short- and long-term
cytotoxicity.
Nanotoxicology is the branch of toxicology born to
precisely address the adverse effects caused by nanomaterials,
in order to contribute to the development of a sustainable and
safe nanotechnology [92]. Indeed, this discipline studies NP-
induced toxicity in in vitro as well as in vivo experimental
models and attempts at optimizing well known toxicity
tests or producing new ones to be applicable for nanosafety
evaluation [73, 93].
In general, toxic effects on cells induced by NP uptake
may depend on particular characteristics of the NP itself;
for example, with respect to the bulk material, NPs possess
higher surface area to volume ratio and surface reactivity and
are more susceptible to degradation or ion leaching [94, 95].
Moreover, frequent NP agglomeration and/or sedimentation
might influence subsequent uptake and lead to cytotoxicity
[96].
The first mechanism of NP-induced cytotoxicity may
derive from how NPs enter the cells. Indeed, some NPs
can be internalized via passive diffusion and possibly lead
to toxicity by directly interacting with the cell cytosol, its
structures, and/or DNA; most types of NPs are instead
endocytosed by cells and confined through clustering in
cytoplasmic vesicles, especially lysosomes or late endosomes
[97, 98]. However, some NPs might be susceptible to the
oxidative environment of these organelles and thus undergo
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degradation or dissolution, resulting in the leaching of free
ions or an increase in reactive surface groups.
A second potential NP toxicity mechanism is actin
cytoskeleton disruption. Due to endocytosis events, the cells
undergo a reorganization of cytoskeleton [99] which plays
a major role in fundamental cellular physiology aspects
of the cell such as shape, motility, division, adhesion, and
connection with the surrounding environment [100]. The
relation between endocytosis and cytoskeleton organization
is highly dynamic and may involve interactions between
distinct protein complexes [101]. As a result, different path-
ways of NPs internalization might lead to the modification
of proteins normally responsible for maintaining cytoskele-
ton organization [102]. Furthermore, the aberration in cell
morphology could result in a decrease in cell migration
[103]. It has to be underlined that the disruption of actin
cytoskeleton is often coupled [104] with the main molecular
mechanism of NP-induced toxicity, that is, the enhancement
of oxidative stress via incremented production of reactive
oxygen species (ROS) [105]. ROS may be generated directly
from free radicals on the surface of NPs; otherwise, NPs
constituted of transition metals like iron NPs may generate
ROS (in particular, hydroxyl radicals) by acting as catalysts
in Fenton-type reactions [106].
Other toxic effects caused by NP uptake, which seem to
be secondary to altered ROS production, are (a) alterations
of gene expression mediated by either direct NP-induced
DNA damage [94, 107, 108] or interaction of NPs with the
cellular transcription/translationmachinery after perinuclear
localization [108, 109], (b) morphological modifications such
as protein denaturation,modulation of intracellular signaling
cascades, or membrane damage [94], and (c) immunological
effects through the upregulation of redox-sensitive transcrip-
tion factors or proinflammatory kinases [110] or the initiation
of an immune response directed to specific proteins localized
in the outside NP corona [111].
Over the last years, research groups that study the
outcomes of NPs used for SCs tracking are focusing on
their possible undesirable effects inside the experimental
model or even the host. Thus, prior to the therapeutic use
of NPs, it is becoming increasingly important to conduct
systematic in vitro studies to assess their toxicological profiles
and evaluate their potential influence on the self-renewal and
differentiation properties of SCs [112, 113].
To show in further detail some examples of biosafety
study of specific nanomaterials in contact with SCs, next
part of this review will focus on selected NPs representing
the most studied products for cell tracking: quantum dots
(QDs), silica NPs, and polymer NPs that are the most used
for fluorescence imaging due to their advantages regarding
quantum yield, brightness, and photostability; superparam-
agnetic iron oxide (SPIO) NPs, which are themost significant
for magnetic resonance imaging; and gold (Au) NPs that are
useful for photoacoustic imaging. In Table 1, we summarize
these different studies.
5.1. Quantum Dots. QDs are highly fluorescent semicon-
ductor NPs, composed of materials from the elements in
the periodic groups of II VI, III V, or IV VI, such as indium
phosphamide (In from group III and P from group V) and
cadmium telluride (Cd from group II and Te from group VI),
and they usually have diameter around 2–10 nm [114]. QDs
possess unique optical and physical properties like narrow
and tunable emission spectra, exceptional photochemical
stability, high quantum yields, and multiplex imaging due to
simultaneous excitation [115, 116]. These platforms have been
incorporated into various assays for the reversible detection
and quantification of biomolecules [117–119] in applications
such as immunoassays [120, 121] and molecular diagnosis
[122] and in clinical assays [123, 124]. When applying QDs
to biological imaging and cellular studies, the toxic nature
of Cd-containing QDs remains a major concern [125]. For
the preparation of biocompatible QDs, the coating of the
CdSe core, with, for instance, a ZnS layer, is indispensable
[126–128] and the quality of the coating might determine the
toxic effects on cultured cells. However, thanks to the recent
advances in the development of surface modifications and
to the production of Cd-free QDs [126–128], the potential
toxicity of Cd itself is long a problem for in vitro and in vivo
imaging studies with QDs.
Based on their favorable properties, QDs have been used
since 1998 [129, 130] for bioimaging applications, in partic-
ular, to label different cell lines for both in vitro and in vivo
studies. Common methods used for an efficient intracellular
delivery of QDs are microinjection, electroporation, lipid-
based transduction, and peptide mediated delivery.
The effects of QDs on SC self-renewal and differentiation
are largely unknown, particularly in embryonic SCs. Some
studies have reported no adverse effects on SC morphology,
viability, proliferation, or differentiation over the duration of
the experiments (from hours to several days) at QD con-
centrations optimized for labeling efficiency [131, 132], while
others have noticed alterations in the differentiation profile of
SCs [133, 134] and abnormalities during embryo development
[135].Therefore, QDs are not completely innocuous, but there
is likely to be a safe range within which they can accomplish
their task without major interference in the processes under
study [135].
Perhaps the broadest effort to study the cytotoxicity of
QDs in SCs has been made using human-derived MSCs
(hMSCs). Some studies have reported that QDs do not
affect cellular proliferation or cell-cycle distribution but do
affect chondrogenic and osteogenic differentiation potential
[133, 134]. However, recent findings indicate that QDs do
not interfere with the differentiation program of SCs [131,
132]. hMSCs labeled with a range of external doses of QDs
conjugated with a cell-penetrating peptide (cholera toxin)
from 250 pM to 16 nM maintained their osteogenic differ-
entiation potential. The cells showed upregulation of alka-
line phosphatase activity, an early osteogenic marker, when
cultured in osteogenic media and expressed the osteogenic
gene Osterix after exposure to BMP-2 [131]. In another study
[132], hMSCs labeled with a concentration of 20–50 nMQDs
were viable and continued to proliferate for at least 22 days
while retaining QDs in their cytoplasm. Furthermore, no
interference of QDs was detected in the differentiation of
hMSCs into osteogenic, chondrogenic, and adipogenic cell
lineages [132]. More recently, Wang et al. [136] labeled MSCs
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isolated from the human amniotic membrane with different
doses of QDs and investigated their effects from 1 to 4
days, observing that the concentration of 0.75𝜇g/mL did
not produce morphological modifications and alteration in
expression of specific surface antigens such as CD29, CD44,
CD90, and CD105, while cells maintained a viability > 80%
[136].
An advantage of cell labeling with QDs is that they can
concurrently tagmultiple inter- and intracellular components
for time ranging from seconds to months and, by using
different coloured QDs, several cell components can be
visualized with fluorescent microscopy or in vivo [137].
In this concern, Shah and Mao [137] provided a detailed
protocol to label selected integrins on the cell membrane
of hMSCs with bioconjugated QDs by optimizing precise
concentration and incubation time. Interestingly, authors
discovered that bioconjugatedQDs effectively labeled hMSCs
not only during population doublings, but also during mul-
tilineage differentiation into osteoblasts, chondrocytes, and
adipocytes. In addition, undifferentiated and differentiated
SCs labeled with bioconjugated QDs could be readily imaged
by fluorescent microscopy.
In a recent study, Chen et al. [138] used silver sulfide
(Ag
2
S)QDs-based secondnear-infraredwindow (NIR-II 1.0–
1.4 𝜇m) imaging to label hMSCs seeded on three-dimensional
(3D) collagen scaffolds. They first assessed cell prolifer-
ation using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay and observed negligible dif-
ference of viability between control and labeled hMSCs
during 30 days of culture on the scaffolds. Furthermore, the
pluripotency-associated transcription factors Nanog, Rex-
1, Oct4, and Sox2 were expressed at similar levels with
respect to unlabeled cells and finally both osteogenic and
adipogenic differentiation of 3D-cultured hMSCs labeled
with Ag
2
S QDs were not different form the control coun-
terparts. After demonstrating that the multipotentiality of
Ag
2
S QDs-labeled hMSCs grown on 3D collagen scaffolds
was maintained, they have applied their labeled cells in an in
vivo experiment that will be elucidated in the next section of
this review.
5.2. Silica NPs. Silica NPs are widely applied in chemical
industry, agriculture, and cosmetics. In addition, they are
being developed in medical uses including diagnosis and
therapy [139, 140], controlled release drug delivery, and gene
transfection [141]. Such medical approaches have numerous
applications including skin cancer therapy [142–144], trans-
dermal drug delivery [145, 146], and gene delivery through
transcutaneous vaccination [147]. They can act as carriers
for drugs with low solubility and might improve drug safety,
stability, and performance [148].
For SCs tracking purposes, silica NPs usually contain
organic dye molecules for fluorescence imaging. In this
system, silica acts as a matrix to chemically and physically
confine the fluorescent dyes. Indeed, the silica partially pro-
tects the dye molecules from external quenchers, enhances
the photostability of incorporated dyes, and, in some cases,
provides a biocompatible and easy-to-functionalize surface
for bioconjugation [149]. Fluorescent silica NPs are mainly
made through two approaches: sol-gel or reverse microemul-
sion. Sol-gel method usually generates fluorescent silica NPs
in the hundreds of nanometers to micron range [150], while
reverse microemulsion strategy provides NPs with diameters
from nanosize to micro size [151–153]. In both methods, the
dye molecules encapsulated inside silica NPs determine their
spectral characteristics.
Cyanine dye-doped silica NPs were reported to label
hMSC without affecting viability, proliferation, stemness
surface marker expression, and differentiation capability into
osteocytes [154]. Moreover, the used silica NPs were able to
directly discriminate between live and early-stage apoptotic
SCs (both mesenchymal and embryonic) through a distinct
external cell surface distribution which makes them ideal for
SC labeling and tracking [154].
A study performed on different cell types [155] demon-
strated that the presence of serum in the cell medium induced
the formation of corona on silica NPs, with subsequent influ-
ence on their cellular uptake level. To evaluate if the presence
and doses of serum during incubation could influence the
uptake level in hMSC, Catalano et al. [156] recently elucidated
the factors ruling the uptake of dye-doped silica NPs by
hMSCs, suggesting different uptake mechanisms involved.
Although the main application of mesoporous silica NPs
is drug delivery [141], there are few studies which used
them for SC tracking. Huang et al. [157] observed the
internalization of mesoporous silica NPs conjugated with
fluorescein isothiocyanate by hMSCs, demonstrating that
there were no differences in cell viability, proliferation, and
immunophenotypic profiles of surface markers with respect
to unlabeled cells. Furthermore, cells retained their capability
to differentiate into adipocytes, chondrocytes, and osteocytes
after NPs internalization. In addition, the uptake mechanism
of these NPs by hMSCs was analysed via different inhibitors
and the roles of clathrin-mediated endocytosis and actin-
dependent endocytosis were demonstrated to be prevalent
[157, 158]. The same group in 2008 [159] reported that silica
NPs can enhance actin polymerization in MSCs and that the
uptake of mesoporous silica NPs into hMSCs did not affect
their osteogenic differentiation.
So far, there are no reports applying fluorescent silica
NPs for in vivo SC tracking. However, on the basis of the
biocompatibility observed especially with MSCs, during the
last years, silica has been employed to cover different types of
NPs and enhance their biocompatibility and cellular uptake,
maintaining the core material characteristics for detection
[160]. For example, in 2008, Liu et al. [161] demonstrated
that silica-coated core-shell superparamagnetic iron oxide
(SPIO@SiO
2
) NPs cocondensed with FITC-incorporated
mesoporous silica were able to enhance the uptake efficiency
of hMSCs, without affecting their viability and differentiation
potential. Similarly, Zhang et al. [162] demonstrated that
mesoporous silica coating facilitated cell uptake of SPIO NPs
and improved cell labeling efficiency in a neuronal progenitor
cell line, with no adverse effects on cell proliferation under
labeling conditions.
Silica NPs have been shown to be useful as ultrasound
contrast agents [163] and even to enhance the photoacoustic
signal generated by gold NPs [164]. Recently, different gold
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NPs have been produced with a silica layer on the gold core,
in order to obtain silica coating, and their characteristics and
biosafety will be further detailed in the “gold NPs” section.
5.3. Polymer NPs. Polymer NPs are generally prepared
through either dispersion of preformed polymers or poly-
merization of monomers [165]. Dendrimers, microgels, and
modified polysaccharide NPs are new polymeric particles
having several medical and practical applications, mostly
used as anticancer drugs, drug and gene delivery carriers, and
magnetic resonance imaging contrast agents once complexed
with Gd(III) [166–170].
For SC tracking in regenerative medicine, fluorescent
organic dyes are commonly used and they could be either
physically entrapped in the polymer interior during the
preparation of NPs or covalently bound to the polymer
chain before the preparation of NPs. Currently, the most
common fluorescent polymer NPs are polystyrene (PS) NPs
that are mainly prepared through the emulsion polymer-
ization method [171]. The uptake of polystyrene NPs by
MSCs was investigated by Jiang et al. [172] using confocal
fluorescence microscopy and flow cytometry. Two types
of aminated particles, PS and NPS (100 nm in diameter),
were synthesized by miniemulsion polymerization process.
Both were functionalized with amino groups by addition
of cetyltrimethylammonium chloride (CTMA) as surfactant,
but a further covalent amino functionalization was carried
out only for NPS by addition of 2-aminoethyl methacrylate
hydrochloride (AEMH). The presence of two different types
of amino groups on NPS surface (physically and covalently
bound by addition of CTMA andAEMH, resp.) did not result
in a significant change of 𝜁-potential values with respect to PS
particles but induced a different behavior of those particles in
relation to the internalization pathway. To assess the relative
importance of specific endocytosis mechanisms, uptake was
observed in the presence of the inhibitor drugs dynasore
and chlorpromazine. Authors found that NPSs were rapidly
internalized and accumulated to amuch higher level inMSCs
than PS NPs, predominantly via clathrin-mediated pathway,
whereas the latter were internalized mainly via clathrin-
independent endocytosis. The pronounced difference in the
internalization behaviour of PS and NPS platforms points to
specific interactions of the amino groups on the NP surface
with the endocytosis machinery of the cells [172].
In addition to PS, fluorescent polymer NPs were also
prepared with conjugated fluorescent polymers exhibiting
amplified fluorescence responses, such as poly(arylene-
diethynlenes) [173], poly(3,4-ethylenedioxythiophene) [174],
poly(thiophene-3-yl-acetic acid) [175], and polyacetylene
[176].
However, despite their wide applications, PS NPs suffer
from low incorporation and inadequate protection of the dye
molecules, with consequent leaching, quenching, and photo-
bleaching of the fluorophores [177], all main disadvantages
for their application in long-term SC tracking.
Recently, a general strategy was reported to enhance
the photostability of organic fluorophores for bioimaging
applications and, as a proof of concept, bright and robust
fluorescence was observed in solid states of a well-defined
synthetic polymer polycaprolactone (PCL) consisting of
di-(thiophene-2-yl)-diketopyrrolopyrrole (DPP) covalently
linked in the middle of the PCL chain as a biocompatible
and bioresorbablematrix [178]. PCL-DPP-PCLNPswere pre-
pared through a nanoprecipitation process of these polymers
and could be internalized by both tumor cells and SCs with
little cytotoxicity.
Reports using fluorescent polymer NPs for SCs labeling
and tracking are still few, but inorganicNPs graftedwith poly-
mer are an area of special interest because of the enhanced
properties of both polymers and NPs. In their review, Francis
et al. [179] covered the general topics of polymer grafted NPs
and their preparation, properties, and applications.
5.4. Superparamagnetic Iron Oxide NPs. SPIO NPs are com-
posed of an iron oxide core, generally of magnetite Fe
3
O
4
or
maghemite 𝛾-Fe
2
O
3
, a coating layer and surface functional
groups that provide NPs with hydrophilicity and stability and
prevent NP aggregation [180, 181]. A coating layer of different
materials, among them, dextran, chitosan, and gelatin, has
been used to stabilize the internal magnetic core [182].
SPIO NPs act as good contrast agents in MRI, enhancing
the contrast between different tissues present by inducing
a darker area (negative contrast). One important feature of
SPIOs is that they lose their magnetization vector induced by
a magnetic field applied and become highly dispersed when
the magnetic field is switched off [183].
SPIO NPs are composed of iron that might be reused/re-
cycled by cells via the principal biochemical pathways
deputed for iron metabolism. Potential mechanisms of iron-
mediated toxicity thus include generation of iron-catalyzed
ROS [184, 185].
So far, SPIOs are the only commercial NPs that have been
regulated for clinical applications [186]. Among commer-
cially available SPIO NPs, the most used as contrast agents
for SC tracking were ferumoxides (Endorem in Europe and
Feridex in the USA, coated with dextrans, with a particle
size of 120 to 180 nm) and ferucarbotran (Resovist, coated
with carboxydextrans, hydrodynamic diameter 62 nm), due
to their approval by the Food and Drug Administration
(FDA) in 2009 for clinical use as liver-specific contrast
agents. Unfortunately, the manufacturers ceased commercial
production of both agents due to commercial reasons. The
clinical development of Ferumoxtran-10 (Combidex in the
USA, Sinerem in Europe), designed for lymph node metas-
tasis evaluation, is currently stopped [187]. NC100150 (Clar-
iscan) is made of SPIO crystals of a magnetite/maghemite
with low molecular weight polyethylene glycol coating on a
carbohydrate residue and its development was discontinued
because of safety issues. Currently, only one type of SPIOs
(ferumoxytol, Feraheme) is marketed for the treatment of
iron deficiency anemia in adult patients with chronic kidney
diseases, rather than for imaging.
Usually, to facilitate incorporation into the cell, SPIOs are
cross-linked with a membrane-translocating signal peptide
(e.g., HIV-1 Tat protein) [188] or incubated in combination
with transfection agents [189].
The cytotoxicity of SPIOs has been evaluated in different
types of SCs, including ESCs [190–192], hMSCs [193, 194], and
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neural SCs (NSCs) [195–197]. Inmost cases, internalization of
these NPs did not affect cell viability and growth.The survival
rate of SCs cultured in a medium containing SPIOs was very
high (97%–99%) indicating that these NPs did not affect cell
viability [198–201]. So far, only one study has demonstrated
that the internalization of SPIOs impaired the differentiation
of SCs. Bulte et al. [202] reported that SPIOs (ferumox-
ides) uptake by hMSCs (intracellular iron incorporation of
13–16 pg Fe/cell), in the presence of the transfection agent
poly-L-lysine, impaired their chondrogenic differentiation.
Although the results of this study suggest that the inhibition
effect was mediated by Fe itself and not by the transfection
agent [202], a study carried out by Arbab et al. [203] proposed
opposite conclusions. Subsequent studies confirmed that the
internalization of SPIOs (ferumoxides) by hMSCs using a
liposome transfection agent did not affect their chondro-
genic, adipogenic, or osteogenic differentiation [204]. Lastly,
Au et al. [205] detected that labeling with SPIOs did not affect
the calcium-handling of cardiomyocytes derived from ESCs,
suggesting the feasibility of in vivo tracking of ESCs inside the
heart with these NPs detected via MRI, without affecting the
cardiac differentiation potential and functional properties of
ESCs.
SPIOs were used to label rabbit MSCs in order to deter-
mine their fate in vivo [200], as described in the next section,
but before that, authors analyzed the NP-associated biosafety.
After 12 hours of incubation with 25𝜇g/mL SPIO NPs (feru-
moxides) and protamine sulphate as transfection agent, more
than 90% of cells were labeled and MTT cytotoxicity and
proliferation assay demonstrated no significant decrease of
proliferation of SPIO-labeled cells compared with unlabeled
cells after 9 days. Moreover, in vitro differentiation analysis
indicated that cell differentiation in adipogenic, osteogenic,
and chondrogenic cell lineages was similar between labeled
and unlabeled rabbit MSCs [200].
Further research conducted by Delcroix et al. [198] in
2009 used SPIO NPs coated with 1-hydroxyethylidene-1.1-
bisphosphonic acid (HEDP) to label ratMSCs (rMSCs). Cells
were incubatedwithNPs for 48 hours and authors established
that more than 90% of cells contained enough iron to
allow their detection without significant alteration of cell
viability. Moreover, cellular ultrastructure was conserved and
the differentiation potential toward osteogenic and neuronal
lineages did not exhibit significant differences with unlabeled
rMSCs. In the same work, authors evaluated the in vivo
application of labeled cells, which will be discussed in next
part of this review.
Since the use of transfection agents to efficiently label
SCs is still an open issue for the biosafety of SPIOs, Ramos-
Go´mez et al. [206] have recently reported the development,
optimization, and validation of an efficient procedure to label
human NSCs with different commercial NPs in the absence
of transfection agents. Authors evaluated the influence of
different concentration of SPIOs on immortalized human
NSCs after 72 hours of exposure and found that the dose
of 50𝜇g/mL did not affect cell survival, evaluated by MTT
assay, and resulted in 80 to 90% labeling efficiency. They also
analyzed whether the presence of SPIOs was compatible with
a normal cell-cycle progression, showing that the distribution
of the percentages of cells in G0-G1, S, and G2-M phases was
the same in labeled and unlabeled cells. Finally, the stemness
and differentiation potentials of hNSCs were not affected.
It is important to underline that different doses of SPIOs
with different types of iron oxide cores and different coating
layers have been used to label diverse cell types, thus not
allowing for obtaining clear indications about themost useful
conditions for their usage. For a better understanding of their
in vitro biosafety, a standard procedure for SC labeling needs
to be identified.
5.5. Gold NPs. The strongly enhanced surface plasmon reso-
nance of Au NPs at optical frequencies makes them excellent
scatterers and absorbers of visible light; moreover, Au NPs
are characterized by ease of synthesis and conjugation to a
variety of biomolecular ligands, antibodies, and other targets,
making them suitable for use in biochemical sensing and
detection, medical diagnostics, therapeutic applications, and
SC tracking. In particular, the most used are gold nanorods
[207]. One other important feature of gold NPs is their ability
to be used for photothermal therapy (PTT), as they can be
induced by infrared light, creating vibrational energy and
heat which in turn kill unwanted cells [208].
For SC labeling, Ricles et al. [209] investigated the func-
tion of MSCs labeled with various formulations of Au NPs
obtained by varying size and poly-L-lysin coating. Results
demonstrated that loading of MSCs with Au nanotracers
(NTs) did not alter cell function and, based on the induc-
tively coupled plasma mass spectrometry results, long-term
imaging and tracking of MSCs were feasible. The same group
in 2012 [210] used noncoated 20 nm Au NTs to label MSCs.
In order to analyze the sensitivity as well as quantification of
the ultrasound and photoacoustic imaging method, labeled
cells were seeded in a tissue mimicking gelatin phantom, a
PEGylated fibrin gel, and they demonstrated that tracking
of viable cells was possible over one week. The in vivo
application will be discussed in the next section.
Jokerst et al. [211] used silica-coated Au nanorods (NRs)
to labelMSCs, demonstrating that silica facilitatedNP uptake
more than 5-fold and increased the photoacoustic signal
of these NPs. Moreover, no toxicity or altered proliferation
was observed and pluripotency in osteogenic and adipogenic
lineage was retained. The analysis of the secretome derived
form labeled hMSCs indicated that only interleukin-6 (IL-
6) was dysregulated more than 2-fold from a pool of 26
cytokines.
More recently, Nam et al. [212] demonstrated that silica
and poly-L-lysin coated SiO
2
Au NRs were able to label
adipose-derived SCs (ASCs) without affecting their viability.
A limitation of Au NPs is that they cannot be employed
with imaging methods of higher resolution, such as MRI.
6. In Vivo Applications of Stem Cells
Labeled with Nanoparticles
In general, NP technology applied for in vivo noninvasive SC
tracking must allow long-term and sensitive localization of
the cells avoiding cytotoxicity as much as possible. In vivo
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preclinical studies are mainly conducted on rodent models
and are performed to optimize the use of NPs starting from
the dose range validated in in vitro experiments.
In preclinical models, it is possible to compare in the
same animal different injection sites and even to transplant
both labeled and unlabeled cells in order to compare their
behavior. Due to the noninvasive real-time analysis of labeled
SCs inside animal models, it is conceivable not only to
follow the migration of injected SCs but also to obtain
information about the long-term outcomes of the treatment,
that is, severalmonths after cell injectionwithout the sacrifice
needed, having also the possibility to confirm the results
obtained using other techniques like histological examina-
tion.Thanks to these characteristics, the use of NPs in in vivo
preclinical experiments could give fundamental information
about optimized dosages, preferred sites of engraftment, and
specialized timing of SC injection, allowing for the tailoring
of treatments to individual patients.
In particular, for regenerative medicine purposes, the
most used modalities to track SCs in vivo are fluorescence,
magnetic resonance, and photoacoustic imaging. We sum-
marize in Table 2 the main studies concerning these different
tracking methods.
6.1. Fluorescence Imaging. Several in vitro and in vivo studies
have used NPs that can be detected using microscopic
optical imaging techniques, including light and fluorescence,
confocal and two-photon microscopy. Compared to other
modalities, optical imaging presents several advantages such
as accessibility for the majority of researchers, low cost, and
high spatial and temporal sensitivity. See reference [213] for
an overview on the recent development of optically active
NPs for SC tracking. For these reasons, in preclinical studies,
fluorescent imaging is currently the most used modality to
follow SCs in vivo. In this concern, the most used fluorescent
NPs to label cells for in vivo application are QDs, silica, and
polymeric NPs.
Many authors have reported tracking of QD-labeled SCs
in vivo; for example, Slotkin et al. [214] developed two tech-
niques to directly label NSCs and progenitor cells (NSPCs)
of the developing mammalian central nervous system with
QDs in vivo. Using in utero ultrasound-guided injection
or electroporation, they successfully QD-labeled ventricular
zone (VZ) and subventricular zone (SVZ) NSPCs of the
mouse embryonic telencephalon. After QD labeling, NSPCs
appeared to continue normally developing, migrating, and
differentiating, as assayed in vivo until embryonic day (E)
18.5 and in neurosphere assays in vitro. Furthermore, authors
revealed that labeling of early mouse embryos with QDs
could be used to mark developing cell populations over time.
In 2007, Rosen et al. [215] reported another approach to
track hMSCs using intracellular QDs upon cardiac rat heart
injection. They demonstrated that single QD-hMSCs could
be easily identified in histologic sections to determine their
location for at least 8 weeks following delivery in vivo and
their 3D spatial distribution could be reconstructed.
More recently, a method for conjugation of high quan-
tum efficiency, photostable, and multispectral QDs was
developed for long-term tracking of endothelial progenitor
cells (EPCs) with improved signal-to-noise ratios [216].
Specifically, authors conjugated fluorescent QDs to acetylated
low-density lipoprotein (acLDL) and used these QD-acLDLs
to label a specificCD34+ subpopulation of EPCs isolated from
rat bone marrow and track them in a rat model of laser-
induced choroidal neovascularization, thereby demonstrat-
ing their potential for tracking EPCs in ocular angiogenesis,
a critical pathologic feature of several blinding conditions.
However, in vivo visualization of the classically used
fluorescent dyes sometimes requires surgical or invasive
procedures that limit in-man studies, essentially because
deep tissue penetration is not obtainable with this optical
approach. Recently, it has been reported that fluorescence
imaging in the second near-infrared window (NIR-II, 1.0–
1.4 𝜇m) might be an ideal strategy for in vivo imaging due
to its deeper tissue penetration and higher temporal and
spatial resolution in comparison with fluorescence imaging
(both in the visible and the first near-infrared windows, NIR-
I, 650–950 nm) and tomographic imaging such as MRI and
positron emission tomography (PET) [138, 217]. For these
reasons, after the biosafety evaluation of Ag
2
S QDs, Chen et
al. [138] used the NIR-II imaging to dynamically visualize the
migration and distribution of labeled hMSCs in response to
stromal derived factor-1𝛼 (SDF-1𝛼), an essential chemokine
regulating SCs migration and homing [218], on cutaneous
wound sites and studied their healing effect. To achieve this
goal, they used a mouse wound healing model implanted
with either unloaded or SDF-1𝛼-loaded collagen scaffolds,
respectively, followed by a comprehensive investigation on
how the concentration and distribution of hMSCs on the
wound site would affect the healing process. First, authors
demonstrated that there were no differences in the tropism
effect of SDF-1𝛼 on the migration of labeled and unlabeled
cells. Then, after in vivo application, they observed a higher
intensity of fluorescence into the wound when the SDF-
1𝛼-loaded collagen scaffold was implanted, indicating that
hMSCs were more actively recruited to the wound site and
they were homogenously distributed. Further, this homoge-
nous distribution of hMSCs in the wound area promoted
the healing process, as shown by optimal wound closure and
thickness of the regenerated epidermis. The authors [138]
underlined that the novel Ag
2
S QDs NIR-II fluorescence
imaging method they developed might turn out to be useful
for future in vivo studies.
6.2. Magnetic Resonance Imaging. MRI is a largely non-
invasive method for human in vivo imaging that uses a
powerful magnetic field to align the nuclear magnetization
of hydrogen atoms which are responsible for the majority of
MR signals [219, 220]; hence, water distribution inside the
body is shown by MRI and correlates with the anatomy of
the body [221]. MRI is often used for diagnosis of different
diseases and to identify cancer metastasis and inflammation
sites [222]. Optimizing scanner parameters or using MRI
contrast agents can enhance contrast between tissues of
interest, allowing for clearer imaging of specific molecules,
cells, or tissues. Indeed, althoughMRI has become one of the
main imaging techniques used in oncology, its resolution is
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mostly insufficient at a molecular and cellular scale, unless
magnetic contrast agents are employed [223].
Magnetic NPs could be categorized as T1 or T2 contrast
agents for MRI depending on the relaxation processes. T2
contrast agents include SPIONPs, bimetallic ferrite NPs (e.g.,
CoFe
2
O
4
,MnFe
2
O
4
, andNiFe
2
O
4
), andhybridmagneticNPs
such as Fe
3
O
4
-Au dumbbell NPs [224]. T1 contrast agents
are primarily gadolinium- (Gd-) containing NPs (e.g., Gd-
chelated lipid NPs, Gd-chelated dextran NPs) and gadolin-
ium oxide NPs [224].
Magnetic NPs are generally used to label SCs before
injection in essentially two ways: (a) surface labeling, in
which NPs are attached to the cell surface, and his method
is very useful for in vitro cell separation but in general it
is unsuitable for in vivo purposes due to rapid reticuloen-
dothelial recognition and subsequent elimination of labeled
cells [225]; (b) internalization of NPs via endocytosis or
phagocytosis.
In general, these contrast agents are applied for SC
tracking because they give a strong signal, offer a direct and
clear cell labeling, and allow noninvasive in vivo scanning.
The details concerning these issues can be found elsewhere
[213, 226].
Different from T2 agents that produce negative signal
(dark spots) on MRI images, Gd-based T1 agents restitute
bright positive signal. As they are bigger compared with
conventional Gd chelates, gadolinium oxide NPs should
warrant higher cell uptake and longer intracellular retention
[227]. However, gadolinium oxide NPs are currently poorly
used for cell tracking due to still insufficient understanding of
their stability in cells and their possible effects on cell function
[181] and, prior to applyingGdNPs in SC therapy, their effects
on SC function need to be fully investigated. As a result, to
date, GadoCellTrack is the only commercially available Gd-
based NP used for experimental in vivo cell tracking.
SPIOs have been used as MRI contrast agents since 1990
[228]. Despite being not initially developed for cell labeling
and tracking, they have been successfully adapted for tracking
SCs after their transplantation [195, 229].
Delcroix et al. [198] investigated how SC tracking in neu-
ral migratory pathways could be potentially used for clinical
therapy. It was already established that MSCs are maintained
in an appropriate environment, composed of specific matrix
molecules and growth factors, and able to transdifferentiate
into neural cells in vitro, though very few works were focused
on the in vivo counterpart. To overcome this limitation, the
authors assessed the migratory potential of labeled rMSCs in
vivo in response to brain neurogenic stimuli. In particular,
cells labeled withHEDP-coated SPIOs were transplanted into
the SVZ of either damaged or nondamaged rat brains and
their migratory activity was assessed. A long-rangemigration
distance of labeled rMSCs was observed in damaged brains,
while no migration was observed in normal brains. Taken
together, this research demonstrated for the first time that
neural migratory pathways could be established and mapped
out using SPIO NPs; however, a limitation of this study
was that the migratory map could only be obtained through
Prussian Blue staining to show iron presence on histological
sections, whereas the in vivo detection of migrating rMSCs
via MRI was precluded by the fact that the mechanical lesion
induced a very important background hyposignal. According
to the authors, precautions will have to be taken in studies
seeking to visualize SPIOs-labeled cells although they did not
observe any adverse effect in the behavior of the animals and
no signs of toxicity were detected in histological sections 21
days after transplantation, therefore confirming the safety of
SPIO NPs for in vivo applications.
Success in SPIO detection with MRI has also been
reported in a ratmodel ofHuntington’s disease [196]. Authors
investigated the effects of SPIO NP (ferumoxides) on human
central nervous system SCs grown as neurospheres (hCNS-
SCns). First, they showed that SPIOs-labeled hCNS-SCns
proliferated and differentiated normally in vitro and exhib-
ited neuronal electrophysiological characteristics. Further-
more, SPIO-labeled hCNS-SCns were then transplanted into
newborn and adult (injured and uninjured) rodent brains
and with both MRI and histology the authors found that
transplanted cells exhibited a similar extent of survival,
migration, integration, and differentiation with respect to
their unlabeled counterparts.
Comparable results were seen in a study by Hu et al.
[230], in which human umbilical cord MSCs (hUC-MSCs)
labeled with SPIOs were transplanted surgically into the
spinal cord of adult rats one day after spinal cord injury. In
vivoMRI conducted 1 and 3 weeks after cell injection showed
a large reduction in signal intensity in the region transplanted
with SPIOs-labeled hUC-MSCs with respect to unlabeled
cells. Transplanted hUC-MSCs engrafted within the injured
spinal cord and survived for at least 8 weeks, led to reduced
spinal cord injury, and promoted muscular-skeletal recovery
if compared with the control group in which no cells were
injected.
Jing et al. [200] after the biosafety study of SPIOs (feru-
moxides) on rabbit MSCs already reported further tracked
labeled cells by in vivoMRI. Labeled autologous rabbit MSCs
were seeded in chitosan and glycerophosphate (C-GP) gels
and then injected into the knee joint cavity of rabbit articular
cartilage defect models. Results showed marked hypointense
signal void areas representing injected MSCs that could
be observed up to 12 weeks. Labeled cells migrated into
the synovial fluid at the suprapatellar bursa, the popliteal
space site, and subchondral bone of femur; however, no cells
were detected in the defect after 12 weeks, suggesting that
autologous MSCs did not actively participate in the repair of
articular cartilage defects following intra-articular injection.
Amsalem and collaborators [231], studying the role of
SCs in myocardial repair, sought to determine whether
the outcome of injected MSCs could be affected by SPIO
NP (ferumoxides) labeling in a rat model of myocardial
infarction. The authors found that after 1, 2, and 4 weeks,
MRI signal showedwell-defined hypointense areas in animals
treated with SPIO-labeled MSCs, while control specimens
injected with either saline or unlabeled MSCs showed no
areas of hypointensities. Retention of the magnetic signal
throughout the 4-week period was observed in all the treated
rats irrespective of myocardial infarction induction.
Chapon et al. [232] used dextran-coated SPIO NPs to
track bone marrowMSCs and determined their effect in host
14 Stem Cells International
cardiac tissue after myocardial infarction. They showed that
the SPIO-labeled MSCs could be easily tracked using MRI
within the first week following myocardial infarction and cell
implantation, while after a few weeks the signal voids were
variable. This may be explained by the dispersion/migration
of the labeled cells after implantation. In addition, radio-
labeled glucose (2-deoxy-2-[F-18] fluoro-D-glucose [FDG])
and positron emission tomography (PET) were used to
determine glucose uptake of the infarcted areas, showing a
greater amount in the hearts transplanted with bone marrow
MSCs compared to infarcted hearts that did not receive the
cells. However, the early increase in FDG uptake did not
persist 6 weeks after infarction, probably as a result of death
of transplanted cells; finally, no improved left ventricular
function was observed in treated rats. Altogether, this study
highlighted both the ability to track SCs by noninvasive
imaging and the importance of using multimodal platforms
to establish the effect of SCs on cardiac function. It is not
clear at the moment what the mechanism responsible for the
(limited) clinical efficacy observed following injection of SCs
into the damaged heart is or whether this might be due to
either a cellular or a humoral response.
In another study of Blocki et al. [233], to overcome the
limited efficacy of cardiac SCs-based therapy due to poor cell
retention, injectable microcapsules were developed for the
delivery of MSCs into the infarcted area. For in vivo appli-
cations, rat MSCs were first labeled with the same dextran-
coated SPIO NPs used by Chapon et al. [232]. Labeled cells
were then injected either as a single cell suspension or within
microcapsules into the injured tissue, as well as in the peri-
infarct area. MSCs injected as single cells were either not
detected at all or only at an early time point after surgery
(two days). In contrast, encapsulated labeled MSCs could
be tracked for the whole duration of the study (six weeks),
although signal intensity decreased over time. Moreover, a
fraction of transplanted labeled MSCs were able to migrate
out of the microcapsules and integrate into the host tissue.
As already discussed in Section 5, Ramos-Go´mez et
al. [206] optimized the labeling of hNSCs with different
SPIO NPs without transfection agents; labeled cells were
then transplanted into the right striatum of a rat model of
Parkinson’s disease, while unlabeled cells were delivered into
the left striatum as an internal imaging control. MRI was
performed at different time points after cell transplantation
(48 h, 2, 4, and 8 weeks), the intensity and size of the signal
decreased slightly during the time period studied, and SPIOs
NP labeled cells were still clearly detectable after 8 weeks.
Moreover, 5 months after cell delivery, a clear hypointense
signal was still visible at the site of transplantation. However,
according to the authors, long-term MR images should be
interpretedwith caution due to the possibility that some SPIO
NPs may have been expelled from the transplanted cells and
internalized by host microglial cells.
An example of application of silica shell on magnetic
NPs (MNP) containing rhodamine B isothiocyanate was
made by Kim et al. [234]. Authors succeeded in tracking
intrasplenically injected bone marrow MSCs labeled with
fluorescent MNP in a liver cirrhosis rat model. As reported
in a previous section, Zhang et al. [162] fabricated fluorescent
mesoporous silica-coated superparamagnetic iron oxide NPs
(fmSiO
4
@SPIONs) for neural stem cell (C17.2) MRI. These
NPs were discrete and uniform in size and had a clear core-
shell structure. When implanted into the right hemisphere
of mice subjected to stroke, contralateral to the ischemic
territory, a small amount of labeled cells could be tracked
while migrating to the injury sites using a clinical MRI
scanner (3 T). Remarkably, labeled cells could be monitored
while homing to the ischemic area even when administered
intravenously. MRI observations were finally corroborated
by fluorescence-based histological sections from brain tissue
[162].
A limitation to the use of SPIO NPs is their occasional
extracellular deposition in tissues, either by active exocytosis
or by passive release due to death of transplanted cells.
Indeed, Berman et al. [235] transplanted SPIO NP-(BioPAL)
labeled C17.2 NSCs into immunodeficient (graft-accepting
Rag2) or immunocompetent (graft-rejecting Balb/c) mice
and observed hypointense voxel signals and bioluminescence
emission over a period of 93 days. Unexpectedly, in mice that
rejected cells, the hypointense MR signal persisted through-
out the entire time course, whereas in the nonrejecting mice
the contrast cleared at a faster rate. In immunocompetent
mice, infiltrating leukocytes and microglia were found to
surround dead cells and to internalize superparamagnetic
iron oxide clusters thus ensuring contrast retention, whereas
in immunodeficient mice proliferation of surviving trans-
planted cells and associated label dilution was supposed to be
at the base of contrast clearance.Thus, interpretation of signal
changes during long-term MR cell tracking is complex and
requires caution. Furthermore, Terrovitis et al. [236] studied
nonimmunoprivileged human and rat cardiac-derived SCs
and hMSCs labeled with both SPIO NPs (ferumoxides)
and 𝛽-galactosidase and injected intramyocardially into
immunocompetent Wistar-Kyoto rats. On day 2, injection
sites of xenogeneic and syngeneic cells (cardiac-derived SCs
and MSCs) were identified by MRI as large intramyocardial
signal voids that persisted for 3 weeks. Histological sec-
tions revealed after 3 weeks the presence of iron-containing
macrophages at the injection site (identified via specificCD68
staining), but very few or no 𝛽-galactosidase-positive SCs
in animals transplanted with syngeneic or xenogeneic cells,
respectively. These results indicated that MRI of ferumoxide-
labeled cells did not reliably report on long-term SCs engraft-
ment in the heart, as deposited iron particles were scavenged
by macrophages, which could then generate a false signal on
MRI.
As an example of their clinical use, SPIO NPs (fer-
umoxides) were used by Janowski et al. [237] for MRI-
tracking of autologous cord blood nucleated cells in a nine-
month-old patient in a permanent vegetative state as a result
of global cerebral ischemia. Cell transplantation into the
right frontal horn of the lateral ventricle resulted in a focal
deposition of cells within the ipsilateral occipital horn, as
detected in 24 h after operative MR scans. Over a period
of 4 months, cell location within the occipital horn did not
change, although a gradual decrease of signal was apparent.
Very few hypointense regions were observed in other parts of
the ventricular system, including the contralateral ventricle
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or the fourth ventricle. At the long-term follow-up visit
(33 months after transplantation), SPIO-related hypointense
signals were no longer detectable; moreover, MRI at that
time did not detect any abnormality that could be attributed
to tumor or overgrowth of transplanted cells and finally
no major changes in the patient’s neurological status were
observed. Despite the poor prognosis, the patient survived
without deterioration for an additional three years.This study
is one of the first clinicalMRI cell tracking trials that aimed to
demonstrate the feasibility of this approach in man. Authors
underlined that an external magnet may possibly be used to
direct SPIO-labeled cells within a fluid compartment such as
the ventricular system.
Another important limitation of SPIO NP application is
that their generated contrast can easily be confounded with
other contrast sources such as bleedings or blood vessels
[238]. Furthermore, since contrast is achieved indirectly
through disturbances of the local magnetic field experienced
by surrounding hydrogen nuclei, quantification of the num-
ber of cells in vivo is questionable [239]. To overcome these
limitations, fluorine (19F) MRI technique could be used,
but at the cost of lower sensitivity [240]. The interest in
19F MRI has been recently increased by the availability of
an FDA-approved 19F nanoemulsion [241]. Perfluorocarbons
(PFCs) have many fluorine atoms with identical chemical
shifts and for this reason they are the most commonly
used for 19F MRI cell tracking applications; PFCs include
perfluoro-15-crown-5-ether, linear perfluoropolyethers, and
perfluorooctyl bromide [242, 243].
Boehm-Sturm et al. [244] labeled human NSCs with per-
fluoropolyether and adultmaleCD1mice thatwere implanted
into the striatum with an injection of either labeled or
unlabeled cells. Authors detected significant 19F signal from
the grafts with labeled cells in all animals, while no signal was
detected from implanted nonlabeled control cells. In mice
with labeled cells grafted in both hemispheres, the 19F signal
persisted at least 6 days after implantation and quantitative
signal-to-noise ratio (SNR) analysis revealed that total 19F
SNRdecreased by<20% fromday 2 to day 6. A detection limit
of 10,000 cells was found in vivo and the location and density
of human cells (hunu+) on histological sections correlated
well with observations in the 19F MR images. Furthermore,
no label-related changes in the numbers of Ki67, nestin,
GFAP, or bIII-tubulin+ cells were detected on histological
sections. However, thorough long-term evaluations of both
effects of PFCs on grafted SCs and efficacy of the labeled cells
in the pathological brain, for example, stroke models, will be
needed in the future.
Overall, there is considerable promising and established
research that demonstrates that magnetic NPs have an
exciting role in SC tracking by noninvasive mechanisms
which could, in time, lead to deeper appreciation of tissue
regeneration pathways and future clinical applications.
6.3. Photoacoustic Imaging. Photoacoustic imaging provides
high detection sensitivity, which allows imaging of down to
100,000 cells in vivo and high spatial and temporal resolution
which are at least an order of magnitude below traditional
cell imaging techniques, such as PET [211]. In photoacoustic
imaging, a photoacoustic wave is generated by thermal
expansion of tissue after absorption of a short laser pulse.The
magnitude of the photoacoustic wave is proportional to the
laser fluency and to the optical absorption coefficient [245].
Because of its low cost, deep penetration (up to 2 cm),
noninvasiveness, and good resolution (100 𝜇m), photoacous-
tic imaging is becoming an alternative method to fluorescent,
MRI, and radioactive imaging for SC in vivo tracking [209–
211].
AuNPs andAu nanorods are potential contrast agents for
photoacoustic imaging [246, 247].
Jokerst et al. [211] used silica-coated Au NRs to label
MSCs before intramuscular injection in mice and obtained
a cell detection limit in vivo of 100,000 cells, which was well
below the clinically relevant numbers.
Nam et al. [210] used a PEGylated fibrin gel containing
Au NP-labeled MSCs to inject intramuscularly the lateral
gastrocnemius of anesthetized Lewis rats and the contrast
brought by Au NPs allowed the researchers to visualize the
in vivo localization of labeled MSCs using photoacoustic
imaging. The authors also performed a longitudinal in vivo
monitoring of the spatial distribution of labeledMSCs at days
3, 7, and 10 after injection, demonstrating the feasibility of this
approach. The same group in 2014 [248] produced a dual Au
NP system which was capable of monitoring both delivered
MSCs and infiltrating macrophages using photoacoustic
imaging. In vitro analysis confirmed preferential labeling of
the two cell types with their respective Au NPs and the
maintenance of cell function following labeling with NPs.
In addition, delivery of the system within a rat hind limb
ischemia model demonstrated the ability to monitor SCs
and distinguish and quantify macrophage infiltration. These
findings were confirmed by histology andmass spectrometry
analysis.
Furthermore, Nam et al. [212] introduced a novel appli-
cation of combined ultrasound and photoacoustic imaging
to assess both burn injury and skin tissue regeneration.
Authors used silica and poly-L-lysin coated SiO
2
NRs,
previously discussed in Section 5, to label ASCs engrafted
within PEGylated fibrin gel and then implanted in a ratmodel
of cutaneous burn injury.The labeled ASCs were successfully
tracked up to 2weeks andwere distinguished fromhost tissue
components (e.g., epidermis, fat, and blood vessels) through
spectroscopic photoacoustic imaging. Imaging-based analy-
sis demonstrated ASCs localization in the top layer of the
skin and a higher density of regenerating blood vessels in the
treated groups.
Overall, these data show that ultrasound and photoa-
coustic imaging-based strategies coupled with Au NRs have
a great potential for SC therapy and tissue engineering due
to noninvasiveness, safety, selectivity, and ability to provide
long-term monitoring.
7. Conclusions
Overall, the results collected in this review show that several
NP-based imaging techniques may potentially highlight the
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position of transplanted SCs and further that, by combining
different imaging techniques such as computed tomogra-
phy, PET, single-photon emission computed tomography
(SPECT), and optical imaging, or ultrasound and photoa-
coustic imaging, a wider array of data could be gathered to
present a clearer picture of biodistribution, differentiation,
cell viability, and function of the cells inside the host.
Indeed, when choosing appropriate SC tracking agents,
it is important to consider their respective imaging require-
ments. The use of magnetic NPs often requires complex
imaging systems, such as MRI, whereas use of fluorescent
NPs relies on optical imaging, which may be more accessible
to the majority of researchers. On the other hand, poor
tissue penetration of fluorescence imagingmightmostly limit
this approach to preclinical analyses. Interestingly, over the
last years, photoacoustic imaging seems to offer low cost,
deep penetration, and good resolution noninvasive imaging
characteristics and it is becoming an alternative method for
SC labeling and in vivo tracking.
Due to contrasting results from cytotoxicity analysis of
various NPs, prior to their therapeutic use as contrast agents
for SC tracking, it is becoming increasingly important to
conduct systematic in vitro and in vivo studies to assess the
toxicological profiles of the chosen NPs and to evaluate their
potential influence on the self-renewal and differentiation
properties of SCs. Future research aimed at optimization of
methods to determine NP toxicity on SCs will be fundamen-
tal to obtain reproducible data and allow stable conclusions
in this emerging field.
In particular, the development of both in vitro and in vivo
nanotoxicology methods should consider specific aspects,
among them, (a) detailed characterization of the specific NP
in terms of composition, shape, size, surface charge, and
content of the outside protein corona; (b) standardization of
both toxicity assays andmethods to produce the samples; and
(c) survey of interferences and discrepancies between NPs
and specific assays and/or their detection methods.
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